Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 0.5% – Here’s What Happened

Posted by Alphonse Anthony on Jul 28th, 2026

Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) shares traded down 0.5% during mid-day trading on Monday . The stock traded as low as $1.8522 and last traded at $1.93. Approximately 14,434 shares changed hands during trading, a decline of 9% from the average daily volume of 15,792 shares. The stock had previously closed at $1.94.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

View Our Latest Analysis on Alaunos Therapeutics

Alaunos Therapeutics Stock Performance

The firm’s 50 day moving average is $2.24 and its two-hundred day moving average is $2.66. The stock has a market capitalization of $47.13 million, a PE ratio of -0.91 and a beta of -1.02.

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.59) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP purchased a new position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned approximately 0.54% of Alaunos Therapeutics as of its most recent SEC filing. 27.72% of the stock is owned by institutional investors and hedge funds.

About Alaunos Therapeutics

(Get Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.